ADC Therapeutics (ADCT) Assets Average (2021 - 2026)

ADC Therapeutics (ADCT) has reported Assets Average for 6 consecutive years, with $307.3 million the latest figure, recorded in Q1 2026.

• Quarterly Assets Average rose 3.39% year-over-year to $307.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307.3 million (up 3.39% YoY) and the FY2025 annual result came in at $322.6 million, down 4.67% from the prior year.
• Assets Average steadied at $307.3 million in Q1 2026 per ADCT's latest filing, from $306.5 million in the prior quarter.
• Over the last five years, Assets Average for ADCT reached as high as $599.9 million in Q1 2022 and fell as low as $297.0 million in Q2 2025.
• A 5-year average of $407.9 million and a median of $360.4 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average grew 23.01% — and 2024, when it sank 30.86%.
• Year by year, Assets Average stood at $511.3 million in 2022, then dropped by 19.65% to $410.8 million in 2023, then decreased by 18.33% to $335.5 million in 2024, then fell by 8.67% to $306.5 million in 2025, then gained by 0.28% to $307.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $307.3 million, $306.5 million, and $305.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.